Motley Fool Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.59M | Sell |
17,288
-3,014
| -15% | -$1.34M | 0.33% | 54 |
|
|
2026
Q1 | $9.07M | Sell |
20,302
-3,301
| -14% | -$1.54M | 0.39% | 56 |
|
|
2025
Q4 | $10.7M | Buy |
23,603
+5,905
| +33% | +$2.55M | 0.42% | 53 |
|
|
2025
Q3 | $6.93M | Buy |
17,698
+1,904
| +12% | +$796K | 0.29% | 77 |
|
|
2025
Q2 | $7.03M | Buy |
15,794
+1,875
| +13% | +$864K | 0.32% | 62 |
|
|
2025
Q1 | $6.75M | Buy |
13,919
+435
| +3% | +$203K | 0.38% | 58 |
|
|
2024
Q4 | $5.43M | Buy |
13,484
+1,840
| +16% | +$853K | 0.28% | 74 |
|
|
2024
Q3 | $5.47M | Buy |
11,644
+613
| +6% | +$294K | 0.32% | 73 |
|
|
2024
Q2 | $5.2M | Buy |
11,031
+2,510
| +29% | +$1.09M | 0.34% | 69 |
|
|
2024
Q1 | $3.56M | Buy |
8,521
+928
| +12% | +$392K | 0.23% | 86 |
|
|
2023
Q4 | $3.09M | Buy |
7,593
+361
| +5% | +$133K | 0.23% | 86 |
|
|
2023
Q3 | $2.51M | Buy |
7,232
+682
| +10% | +$239K | 0.2% | 89 |
|
|
2023
Q2 | $2.31M | Buy |
+6,550
| New | +$2.21M | 0.21% | 86 |
|
|
2023
Q1 | – | Sell |
-6,303
| Closed | -$1.82M | – | 203 |
|
|
2022
Q4 | $1.82M | Sell |
6,303
-190
| -3% | -$57.9K | 0.21% | 86 |
|
|
2022
Q3 | $1.88M | Sell |
6,493
-47
| -0.7% | -$13.5K | 0.18% | 90 |
|
|
2022
Q2 | $1.89M | Sell |
6,540
-245
| -4% | -$65.6K | 0.18% | 95 |
|
|
2022
Q1 | $1.77M | Buy |
6,785
+195
| +3% | +$46.3K | 0.13% | 110 |
|
|
2021
Q4 | $1.45M | Buy |
6,590
+53
| +0.8% | +$10.3K | 0.09% | 123 |
|
|
2021
Q3 | $1.19M | Buy |
6,537
+365
| +6% | +$71.3K | 0.08% | 135 |
|
|
2021
Q2 | $1.24M | Buy |
6,172
+168
| +3% | +$35.1K | 0.08% | 130 |
|
|
2021
Q1 | $1.29M | Sell |
6,004
-89
| -1% | -$19.5K | 0.09% | 120 |
|
|
2020
Q4 | $1.44M | Buy |
6,093
+511
| +9% | +$117K | 0.11% | 109 |
|
|
2020
Q3 | $1.53M | Buy |
5,582
+663
| +13% | +$183K | 0.14% | 97 |
|
|
2020
Q2 | $1.43M | Buy |
4,919
+623
| +15% | +$169K | 0.14% | 90 |
|
|
2020
Q1 | $1.02M | Sell |
4,296
-341
| -7% | -$78.2K | 0.13% | 102 |
|
|
2019
Q4 | $1.01M | Hold |
4,637
| – | – | 0.11% | 105 |
|
|
2019
Q3 | $786K | Buy |
4,637
+362
| +8% | +$64K | 0.09% | 115 |
|
|
2019
Q2 | $784K | Buy |
4,275
+322
| +8% | +$56.3K | 0.09% | 118 |
|
|
2019
Q1 | $727K | Buy |
3,953
+854
| +28% | +$158K | 0.08% | 116 |
|
|
2018
Q4 | $514K | Buy |
3,099
+294
| +10% | +$50.9K | 0.07% | 122 |
|
|
2018
Q3 | $541K | Buy |
2,805
+130
| +5% | +$23.1K | 0.07% | 110 |
|
|
2018
Q2 | $455K | Buy |
2,675
+420
| +19% | +$65.1K | 0.06% | 113 |
|
|
2018
Q1 | $368K | Buy |
+2,255
| New | +$368K | 0.05% | 117 |
|
Other funds holding VRTX
Motley Fool Asset Management's VRTX Position: Q2 2026 in Review
Motley Fool Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 15% in Q2 2026, selling an estimated $1.34M and leaving 17,288 shares worth $8.59M. The position accounts for 0.33% of the portfolio, ranked #54.
Motley Fool Asset Management first reported a position in VRTX in Q1 2018 and has held it in 33 quarters since. The position peaked at $10.7M in Q4 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Motley Fool Asset Management held 17,288 shares of Vertex Pharmaceuticals worth $8.59M as of Q2 2026.
- Motley Fool Asset Management sold 3,014 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.34M.
- Vertex Pharmaceuticals made up 0.33% of Motley Fool Asset Management's portfolio in Q2 2026, its #54 holding.
- Motley Fool Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
- Motley Fool Asset Management's Vertex Pharmaceuticals position peaked at $10.7M in Q4 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Motley Fool Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.